Search

Your search keyword '"Galimberti, Viviana"' showing total 9 results
Start Over Author "Galimberti, Viviana" Publication Type Electronic Resources
9 results on '"Galimberti, Viviana"'

1. Male breast cancer: a multicenter study to provide a guide for proper management

Author

Lissidini, G, Nicosia, L, Sargenti, M, Cucchi, M, Fabi, A, Falco, G, Gardani, M, Grilz, G, Maugeri, I, Murgo, R, Neri, A, Pellini, F, Sensi, C, Scomersi, S, Taffurelli, M, Bagnardi, V, Oriecuia, C, Pagan, E, Sangalli, C, Dessena, M, Veronesi, P, Galimberti, V, Lissidini, Germana, Nicosia, Luca, Sargenti, Manuela, Cucchi, Maria Cristina, Fabi, Alessandra, Falco, Giuseppe, Gardani, Marco, Grilz, Greta, Maugeri, Ilaria, Murgo, Roberto, Neri, Alessandro, Pellini, Francesca, Sensi, Cristiana, Scomersi, Serena, Taffurelli, Mario, Bagnardi, Vincenzo, Oriecuia, Chiara, Pagan, Eleonora, Sangalli, Claudia, Dessena, Massimo, Veronesi, Paolo, Galimberti, Viviana, Lissidini, G, Nicosia, L, Sargenti, M, Cucchi, M, Fabi, A, Falco, G, Gardani, M, Grilz, G, Maugeri, I, Murgo, R, Neri, A, Pellini, F, Sensi, C, Scomersi, S, Taffurelli, M, Bagnardi, V, Oriecuia, C, Pagan, E, Sangalli, C, Dessena, M, Veronesi, P, Galimberti, V, Lissidini, Germana, Nicosia, Luca, Sargenti, Manuela, Cucchi, Maria Cristina, Fabi, Alessandra, Falco, Giuseppe, Gardani, Marco, Grilz, Greta, Maugeri, Ilaria, Murgo, Roberto, Neri, Alessandro, Pellini, Francesca, Sensi, Cristiana, Scomersi, Serena, Taffurelli, Mario, Bagnardi, Vincenzo, Oriecuia, Chiara, Pagan, Eleonora, Sangalli, Claudia, Dessena, Massimo, Veronesi, Paolo, and Galimberti, Viviana

Abstract

Introduction: To offer an extensive retrospective experience on the management of male breast cancer. Methods: A multicenter retrospective observational cohort study was conducted, including male patients diagnosed with breast cancer (invasive or in situ) in 12 Italian breast units from January 1975 to December 2019. Patients aged 18 years or older were assessed for eligibility. Exclusion criteria were metastatic cancer at diagnosis, previous cancer(s), received neoadjuvant treatment, incomplete data on (neo) adjuvant treatment(s), and/or follow-up data. Data on radiological examinations, demographic characteristics, risk factors, histological features, receptor status, treatments, and follow-up were collected. Results: In a series of 671 male patients with breast cancer assessed for eligibility, 403 (28 in situ and 375 invasive neoplasms) were included in the study. All included patients underwent surgery. The median age at surgery was 63.8 years (IQR 56.1–72.1). In 68% of cases, patients underwent echography, and in 55.1%, a mammography. Most patients were ER and PR positive (63.8%), HER2 negative (80.4%), with high (≥ 20%) Ki67 values (61.3%), and luminal B subtype (51.1%). The 10-year overall survival was 73.6% (95% CI 67.0–79.1) for invasive breast cancer and 90% (95% CI 65.6–97.4) for in situ breast cancer. In patients with invasive breast cancer, at univariable analysis, having a G3 tumor (vs. G1), pT2/3/4 (vs. pT1), pN2/3 (vs. pN0), luminal B subtype with Ki67 ≥ 20% (vs. Luminal A), were significantly associated with a higher risk of death. In multivariable analyses, pT2/3/4 (vs. pT1) remained significantly associated with a higher risk of death (HR 3.14, 95% CI 1.83–5.39), and having a HER2 positive or a triple-negative subtype (vs. Luminal A) was also significantly associated with a higher risk of mortality (HR 4.76, 95% CI 1.26–18.1). Conclusion: Male breast cancer is a rare disease, the better understanding of which is necessary for a more effective diag

Published
2024

2. Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapy

Author

Weber, Walter Paul, Shaw, Jane, Pusic, Andrea, Wyld, Lynda, Morrow, Monica, King, Tari, Mátrai, Zoltán, Heil, Jörg, Fitzal, Florian, Potter, Shelley, Rubio, Isabel T., Cardoso, Maria Joao, Gentilini, Oreste Davide, Galimberti, Viviana, Sacchini, Virgilio, Rutgers, Emiel J.T., Benson, John, Allweis, Tanir M., Haug, Martin, Paulinelli, Regis R., Kovacs, Tibor, Harder, Yves, Gulluoglu, Bahadir M., Gonzalez, Eduardo, Faridi, Andree, Elder, Elisabeth, Dubsky, Peter, Blohmer, Jens Uwe, Bjelic-Radisic, Vesna, Barry, Mitchel, Hay, Susanne Dieroff, Bowles, Kimberly, French, James, Reitsamer, Roland, Koller, Rupert, Schrenk, Peter, Kauer-Dorner, Daniela, Biazus, Jorge, Brenelli, Fabricio, Letzkus, Jaime, Saccilotto, Ramon, Joukainen, Sarianna, Kauhanen, Susanna, Karhunen-Enckell, Ulla, Hoffmann, Juergen, Kneser, Ulrich, Kühn, Thorsten, Kontos, Michalis, Tampaki, Ekaterini Christina, Carmon, Moshe, Hadar, Tal, Catanuto, Giuseppe, Garcia-Etienne, Carlos A., Koppert, Linetta, Gouveia, Pedro F., Lagergren, Jakob, Svensjö, Tor, Maggi, Nadia, Kappos, Elisabeth A., Schwab, Fabienne D., Castrezana, Liliana, Steffens, Daniel, Krol, Janna, Tausch, Christoph, Günthert, Andreas, Knauer, Michael, Katapodi, Maria C., Bucher, Susanne, Hauser, Nik, Kurzeder, Christian, Mucklow, Rosine, Tsoutsou, Pelagia G., Sezer, Atakan, Çakmak, Güldeniz Karadeniz, Karanlik, Hasan, Fairbrother, Patricia, Romics, Laszlo, Montagna, Giacomo, Urban, Cicero, Walker, Melanie, Formenti, Silvia C., Gruber, Guenther, Zimmermann, Frank, Zwahlen, Daniel Rudolf, Kuemmel, Sherko, El-Tamer, Mahmoud, Vrancken Peeters, Marie Jeanne, Kaidar-Person, Orit, Gnant, Michael, Poortmans, Philip, de Boniface, Jana, Weber, Walter Paul, Shaw, Jane, Pusic, Andrea, Wyld, Lynda, Morrow, Monica, King, Tari, Mátrai, Zoltán, Heil, Jörg, Fitzal, Florian, Potter, Shelley, Rubio, Isabel T., Cardoso, Maria Joao, Gentilini, Oreste Davide, Galimberti, Viviana, Sacchini, Virgilio, Rutgers, Emiel J.T., Benson, John, Allweis, Tanir M., Haug, Martin, Paulinelli, Regis R., Kovacs, Tibor, Harder, Yves, Gulluoglu, Bahadir M., Gonzalez, Eduardo, Faridi, Andree, Elder, Elisabeth, Dubsky, Peter, Blohmer, Jens Uwe, Bjelic-Radisic, Vesna, Barry, Mitchel, Hay, Susanne Dieroff, Bowles, Kimberly, French, James, Reitsamer, Roland, Koller, Rupert, Schrenk, Peter, Kauer-Dorner, Daniela, Biazus, Jorge, Brenelli, Fabricio, Letzkus, Jaime, Saccilotto, Ramon, Joukainen, Sarianna, Kauhanen, Susanna, Karhunen-Enckell, Ulla, Hoffmann, Juergen, Kneser, Ulrich, Kühn, Thorsten, Kontos, Michalis, Tampaki, Ekaterini Christina, Carmon, Moshe, Hadar, Tal, Catanuto, Giuseppe, Garcia-Etienne, Carlos A., Koppert, Linetta, Gouveia, Pedro F., Lagergren, Jakob, Svensjö, Tor, Maggi, Nadia, Kappos, Elisabeth A., Schwab, Fabienne D., Castrezana, Liliana, Steffens, Daniel, Krol, Janna, Tausch, Christoph, Günthert, Andreas, Knauer, Michael, Katapodi, Maria C., Bucher, Susanne, Hauser, Nik, Kurzeder, Christian, Mucklow, Rosine, Tsoutsou, Pelagia G., Sezer, Atakan, Çakmak, Güldeniz Karadeniz, Karanlik, Hasan, Fairbrother, Patricia, Romics, Laszlo, Montagna, Giacomo, Urban, Cicero, Walker, Melanie, Formenti, Silvia C., Gruber, Guenther, Zimmermann, Frank, Zwahlen, Daniel Rudolf, Kuemmel, Sherko, El-Tamer, Mahmoud, Vrancken Peeters, Marie Jeanne, Kaidar-Person, Orit, Gnant, Michael, Poortmans, Philip, and de Boniface, Jana

Abstract

Aim: Demand for nipple- and skin- sparing mastectomy (NSM/SSM) with immediate breast reconstruction (BR) has increased at the same time as indications for post-mastectomy radiation therapy (PMRT) have broadened. The aim of the Oncoplastic Breast Consortium initiative was to address relevant questions arising with this clinically challenging scenario. Methods: A large global panel of oncologic, oncoplastic and reconstructive breast surgeons, patient advocates and radiation oncologists developed recommendations for clinical practice in an iterative process based on the principles of Delphi methodology. Results: The panel agreed that surgical technique for NSM/SSM should not be formally modified when PMRT is planned with preference for autologous over implant-based BR due to lower risk of long-term complications and support for immediate and delayed-immediate reconstructive approaches. Nevertheless, it was strongly believed that PMRT is not an absolute contraindication for implant-based or other types of BR, but no specific recommendations regarding implant positioning, use of mesh or timing were made due to absence of high-quality evidence. The panel endorsed use of patient-reported outcomes in clinical practice. It was acknowledged that the shape and size of reconstructed breasts can hinder radiotherapy planning and attention to details of PMRT techniques is important in determining aesthetic outcomes after immediate BR.

Published
2022

3. How to Perform Repeat Sentinel Node Biopsy Safely After a Previous Mastectomy: Technical Features and Oncologic Outcomes

Author

Vicini, E, Leonardi, M, Fontana, S, Pagan, E, Bagnardi, V, Gilardi, L, Cardillo, A, Rafaniello Raviele, P, Sargenti, M, Morigi, C, Intra, M, Veronesi, P, Galimberti, V, Vicini, Elisa, Leonardi, Maria Cristina, Fontana, Sabrina Kahler Ribeiro, Pagan, Eleonora, Bagnardi, Vincenzo, Gilardi, Laura, Cardillo, Anna, Rafaniello Raviele, Paola, Sargenti, Manuela, Morigi, Consuelo, Intra, Mattia, Veronesi, Paolo, Galimberti, Viviana, Vicini, E, Leonardi, M, Fontana, S, Pagan, E, Bagnardi, V, Gilardi, L, Cardillo, A, Rafaniello Raviele, P, Sargenti, M, Morigi, C, Intra, M, Veronesi, P, Galimberti, V, Vicini, Elisa, Leonardi, Maria Cristina, Fontana, Sabrina Kahler Ribeiro, Pagan, Eleonora, Bagnardi, Vincenzo, Gilardi, Laura, Cardillo, Anna, Rafaniello Raviele, Paola, Sargenti, Manuela, Morigi, Consuelo, Intra, Mattia, Veronesi, Paolo, and Galimberti, Viviana

Abstract

Background: The latest National Comprehensive Cancer Network Breast Cancer Guidelines still discourage repeat sentinel node biopsy (SNB) after mastectomy, and the largest multicentric study available reports only 35 cases in the absence of previous axillary dissection (AD). Methods: From January 2003 to November 2018, 89 patients of the European Institute of Oncology with local recurrence of breast cancer after mastectomy, free of distant metastases, with a clinically negative axilla and a negative axillary ultrasound, in absence of AD, underwent lymphatic mapping before wide local excision. Results: During surgery, SNB was successful for 99% of the patients, with 14% being metastatic. Additional metastatic nodes removed by AD after a positive sentinel node occurred in 82% of cases. After a medium follow-up period of 3.7 years, the overall survival rate was 96.7%, and the disease-free survival rate was 84.4%. No axillary relapse after AD was recorded. One patient who refused human epidermal growth factor receptor 2 (HER2)-targeted treatment experienced ipsilateral axillary recurrence after a negative repeat SNB. The first axillary level was never directly irradiated because all the patients with positive repeat SNB underwent AD. For invasive luminal-like HER2-negative recurrences, the metastatic sentinel node was significantly associated with the choice to prescribe adjuvant chemotherapy (p = 0.003). Conclusions: In specialized centers, repeat axillary SNB for patients with local recurrence after mastectomy in the absence of previous AD can represent a safe option for detection and removal of occult axillary disease that would otherwise not be excised/irradiated to achieve better local control and could possibly influence the choice of adjuvant treatments.

Published
2022

4. Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up

Author

Kahler-Ribeiro-Fontana, S, Pagan, E, Magnoni, F, Vicini, E, Morigi, C, Corso, G, Intra, M, Canegallo, F, Ratini, S, Leonardi, M, La Rocca, E, Bagnardi, V, Montagna, E, Colleoni, M, Viale, G, Bottiglieri, L, Grana, C, Biasuz, J, Veronesi, P, Galimberti, V, Kahler-Ribeiro-Fontana, Sabrina, Pagan, Eleonora, Magnoni, Francesca, Vicini, Elisa, Morigi, Consuelo, Corso, Giovanni, Intra, Mattia, Canegallo, Fiorella, Ratini, Silvia, Leonardi, Maria Cristina, La Rocca, Eliana, Bagnardi, Vincenzo, Montagna, Emilia, Colleoni, Marco, Viale, Giuseppe, Bottiglieri, Luca, Grana, Chiara Maria, Biasuz, Jorge Villanova, Veronesi, Paolo, Galimberti, Viviana, Kahler-Ribeiro-Fontana, S, Pagan, E, Magnoni, F, Vicini, E, Morigi, C, Corso, G, Intra, M, Canegallo, F, Ratini, S, Leonardi, M, La Rocca, E, Bagnardi, V, Montagna, E, Colleoni, M, Viale, G, Bottiglieri, L, Grana, C, Biasuz, J, Veronesi, P, Galimberti, V, Kahler-Ribeiro-Fontana, Sabrina, Pagan, Eleonora, Magnoni, Francesca, Vicini, Elisa, Morigi, Consuelo, Corso, Giovanni, Intra, Mattia, Canegallo, Fiorella, Ratini, Silvia, Leonardi, Maria Cristina, La Rocca, Eliana, Bagnardi, Vincenzo, Montagna, Emilia, Colleoni, Marco, Viale, Giuseppe, Bottiglieri, Luca, Grana, Chiara Maria, Biasuz, Jorge Villanova, Veronesi, Paolo, and Galimberti, Viviana

Abstract

Introduction: In patients with positive lymph nodes (cN+) prior to neoadjuvant treatment (NAT), which convert to a clinically negative axilla (cN0) after treatment, the use of sentinel node biopsy (SNB) is still debatable, since the false-negative rate (FNR) is significantly high (12.6–14.2%). The objective of this retrospective mono-institutional study, with a long follow-up, aimed to evaluate the outcome in patients undergoing NAT who remained or converted to cN0 and received SNB independent of target axillary dissection (TAD) or the removal of at least 3 sentinel nodes (SNs). Methods: This study analyzed 688 consecutive cT1-3, cN0/1/2 patients, operated at the European Institute of Oncology, Milan, from 2000 to 2015 who became or remained cN0 after NAT and underwent SNB with a least one SN found. Axillary dissection (AD) was not performed if the SN was negative. Nodal radiotherapy (RT) was not mandatory. Results: Axillary failure occurred in 1.8% of the initially cN1/2 patients and in 1.5% of the initially cN0 patients. After a median follow-up of 9.2 years (IQR 5.3–12.3), the 5- and 10-year overall survival (OS) were 91.3% (95% CI, 88.8–93.2) and 81.0% (95% CI, 77.2–84.2) in the whole cohort, 92.0% (95% CI, 89.0–94.2) and 81.5% (95% CI, 76.9–85.2) in those initially cN0, 89.8% (95% CI, 85.0–93.2) and 80.1% (95% CI, 72.8–85.7) in those initially cN1/2. Conclusion: The 10-year follow-up confirmed our preliminary data that the use of standard SNB is acceptable in cN1/2 patients who become cN0 after NAT and will not translate into a worse outcome.

Published
2021

5. Customizing local and systemic therapies for women with early breast cancer:the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021

Author

Burstein, H. J., Curigliano, Giuseppe, Thürlimann, B., Weber, W. P., Poortmans, Philip, Regan, Meredith, Senn, H. J., Winer, E. P., Gnant, M., Aebi, Stephan, André, Fabrice, Barrios, Carlos, Bergh, Jonas, Bonnefoi, Herve, Bretel Morales, Denisse, Brucker, Sara, Burstein, Harold, Cameron, David, Cardoso, Fatima, Carey, Lisa, Chua, Boon, Ciruelos, Eva, Colleoni, Marco, Delaloge, Suzette, Denkert, Carsten, Dubsky, Peter, Ejlertsen, Bent, Fitzal, Florian, Francis, Prudence, Galimberti, Viviana, Gamal El Din Mohamed Mahmoud, Hebatallah, Garber, Judy, Gnant, Michael, Gradishar, William, Gulluoglu, Bahadir, Harbeck, Nadia, Huang, Chiun Sheng, Huober, Jens, Ilbawi, Andre, Jiang, Zefei, Johnston, Steven, Lee, Eun Sook, Loibl, Sibylle, Morrow, Monica, Partridge, Ann, Piccart, Martine, Prat, Aleix, Burstein, H. J., Curigliano, Giuseppe, Thürlimann, B., Weber, W. P., Poortmans, Philip, Regan, Meredith, Senn, H. J., Winer, E. P., Gnant, M., Aebi, Stephan, André, Fabrice, Barrios, Carlos, Bergh, Jonas, Bonnefoi, Herve, Bretel Morales, Denisse, Brucker, Sara, Burstein, Harold, Cameron, David, Cardoso, Fatima, Carey, Lisa, Chua, Boon, Ciruelos, Eva, Colleoni, Marco, Delaloge, Suzette, Denkert, Carsten, Dubsky, Peter, Ejlertsen, Bent, Fitzal, Florian, Francis, Prudence, Galimberti, Viviana, Gamal El Din Mohamed Mahmoud, Hebatallah, Garber, Judy, Gnant, Michael, Gradishar, William, Gulluoglu, Bahadir, Harbeck, Nadia, Huang, Chiun Sheng, Huober, Jens, Ilbawi, Andre, Jiang, Zefei, Johnston, Steven, Lee, Eun Sook, Loibl, Sibylle, Morrow, Monica, Partridge, Ann, Piccart, Martine, and Prat, Aleix

Abstract

The 17th St Gallen International Breast Cancer Consensus Conference in 2021 was held virtually, owing to the global COVID-19 pandemic. More than 3300 participants took part in this important bi-annual critical review of the ‘state of the art’ in the multidisciplinary care of early-stage breast cancer. Seventy-four expert panelists (see Appendix 1) from all continents discussed and commented on the previously elaborated consensus questions, as well as many key questions on early breast cancer diagnosis and treatment asked by the audience. The theme of this year's conference was ‘Customizing local and systemic therapies.’ A well-organized program of pre-recorded symposia, live panel discussions and real-time panel voting results drew a worldwide audience of thousands, reflecting the far-reaching impact of breast cancer on every continent. The interactive technology platform allowed, for the first time, audience members to ask direct questions to panelists, and to weigh in with their own vote on several key panel questions. A hallmark of this meeting was to focus on customized recommendations for treatment of early-stage breast cancer. There is increasing recognition that the care of a breast cancer patient depends on highly individualized clinical features, including the stage at presentation, the biological subset of breast cancer, the genetic factors that may underlie breast cancer risk, the genomic signatures that inform treatment recommendations, the extent of response before surgery in patients who receive neoadjuvant therapy, and patient preferences. This customized approach to treatment requires integration of clinical care between patients and radiology, pathology, genetics, and surgical, medical and radiation oncology providers. It also requires a dynamic response from clinicians as they encounter accumulating clinical information at the time of diagnosis and then serially with each step in the treatment plan and follow-up, reflecting patient experiences a

Published
2021

6. Prognosis of selected triple negative apocrine breast cancer patients who did not receive adjuvant chemotherapy

Author

Montagna, E, Cancello, G, Pagan, E, Bagnardi, V, Munzone, E, Dellapasqua, S, Viale, G, Mazzarol, G, Veronesi, P, Galimberti, V, Santomauro, G, Colleoni, M, Montagna, Emilia, Cancello, Giuseppe, Pagan, Eleonora, Bagnardi, Vincenzo, Munzone, Elisabetta, Dellapasqua, Silvia, Viale, Giuseppe, Mazzarol, Giovanni, Veronesi, Paolo, Galimberti, Viviana, Santomauro, Giorgia, Colleoni, Marco, Montagna, E, Cancello, G, Pagan, E, Bagnardi, V, Munzone, E, Dellapasqua, S, Viale, G, Mazzarol, G, Veronesi, P, Galimberti, V, Santomauro, G, Colleoni, M, Montagna, Emilia, Cancello, Giuseppe, Pagan, Eleonora, Bagnardi, Vincenzo, Munzone, Elisabetta, Dellapasqua, Silvia, Viale, Giuseppe, Mazzarol, Giovanni, Veronesi, Paolo, Galimberti, Viviana, Santomauro, Giorgia, and Colleoni, Marco

Abstract

Background: Triple negative breast cancer encompasses several biological entities with different outcomes and is a priority to identify which patients require more treatment to reduce the risk of recurrence and which patients need less treatment. Patients and methods: Among the 210 women with first primary invasive apocrine non metastatic breast cancer operated on between January 1998 and December 2016 at the European Institute Oncology, Milan, we identified 24 patients with a pT1-pT2, node-negative, triple negative subtype and Ki-67 ≤ 20% who did not receive adjuvant chemotherapy (CT). We compared the outcome of this cohort with a similar group of 24 patients with ductal tumors who received adjuvant chemotherapy, matched by pathological stage and biological features and also with a similar group of 12 patients with apocrine tumors who received adjuvant chemotherapy. Results: The median age was 64 and 61 years in the apocrine (w/o CT) and ductal group, respectively. The median value of Ki-67 expression was 12% in the apocrine group (w/o CT) and 16% in the ductal group (p < 0.001). After a median follow-up of 7.5 years, no patients in the apocrine group (w/o CT) experienced a breast cancer related event compared with 4 events in the ductal carcinoma group (Gray test p-value = 0.11). Conclusions: The outcome of selected apocrine triple negative breast cancer patients who did not received adjuvant chemotherapy is excellent and supports a treatment de-escalation. Multicenter projects focusing on the possibility of avoiding adjuvant chemotherapy in selected subtypes of triple negative breast cancers with favorable outcome are warranted.

Published
2020

7. Oncological Outcomes of Nipple-Sparing Mastectomy: A Single-Center Experience of 1989 Patients

Author

Galimberti, V, Morigi, C, Bagnardi, V, Corso, G, Vicini, E, Fontana, S, Naninato, P, Ratini, S, Magnoni, F, Toesca, A, Kouloura, A, Rietjens, M, De Lorenzi, F, Vingiani, A, Veronesi, P, Galimberti, Viviana, Morigi, Consuelo, Bagnardi, Vincenzo, Corso, Giovanni, Vicini, Elisa, Fontana, Sabrina Kahler Ribeiro, Naninato, Paola, Ratini, Silvia, Magnoni, Francesca, TOESCA, ANTONIO, Kouloura, Andriana, Rietjens, Mario, De Lorenzi, Francesca, Vingiani, Andrea, Veronesi, Paolo, Galimberti, V, Morigi, C, Bagnardi, V, Corso, G, Vicini, E, Fontana, S, Naninato, P, Ratini, S, Magnoni, F, Toesca, A, Kouloura, A, Rietjens, M, De Lorenzi, F, Vingiani, A, Veronesi, P, Galimberti, Viviana, Morigi, Consuelo, Bagnardi, Vincenzo, Corso, Giovanni, Vicini, Elisa, Fontana, Sabrina Kahler Ribeiro, Naninato, Paola, Ratini, Silvia, Magnoni, Francesca, TOESCA, ANTONIO, Kouloura, Andriana, Rietjens, Mario, De Lorenzi, Francesca, Vingiani, Andrea, and Veronesi, Paolo

Abstract

Background: Nipple-sparing mastectomy (NSM) is increasingly used in women with breast cancer who are not eligible for conservative surgery, but extensive outcome data are lacking and indications have not been established. Objective: The aim of this study was to assess the oncological outcomes of NSM in a large series of patients with invasive or in situ breast cancer treated at a single center. Methods: We analyzed 1989 consecutive women who had an NSM in 2003–2011, for invasive (1711 patients) or in situ cancer (278 patients) at the European Institute of Oncology, Italy, and followed-up to December 2016. Endpoints were local recurrences, recurrences in the nipple-areola complex (NAC), NAC necrosis, and overall survival (OS). Results: After a median follow-up of 94 months (interquartile range 70–117), 91/1711 (5.3%) patients with invasive cancer had local recurrence (4.8% invasive disease, 0.5% in situ disease), and 11/278 (4.0%) patients with in situ disease had local recurrence (1.8% invasive disease, 2.2% in situ disease). Thirty-six (1.8%) patients had NAC recurrence, 9 with in situ disease (4 invasive and 5 in situ recurrences), and 27 with invasive disease (18 invasive and 9 in situ recurrences). NAC loss for necrosis occurred in 66 (3.3%) patients. There were 131 (6.6%) deaths, 109 (5.5%) as a result of breast cancer. OS at 5 years was 96.1% in women with invasive cancer and 99.2% in women with in situ disease. Conclusions: The findings in this large series, with a median follow-up of nearly 8 years, indicate that NSM is oncologically safe for selected patients. The rate of NAC loss was acceptably low.

Published
2018

8. Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

Author

Coates, A. S., Winer, E. P., Goldhirsch, A., Gelber, R. D., Gnant, M., Piccart-Gebhart, M., Thürlimann, B., Senn, H.-J, André, Fabrice, Baselga, José, Bergh, Jonas, Bonnefoi, Hervé, Burstein, Harold, Cardoso, Fatima, Castiglione-Gertsch, Monica, Coates, Alan S., Colleoni, Marco, Curigliano, Giuseppe, Davidson, Nancy E., Di Leo, Angelo, Ejlertsen, Bent, Forbes, John F., Galimberti, Viviana, Gelber, Richard D., Gnant, Michael, Goldhirsch, Aron, Goodwin, Pamela, Harbeck, Nadia, Hayes, Daniel F., Huober, Jens, Hudis, Clifford A., Ingle, James N., Jassem, Jacek, Jiang, Zefei, Karlsson, Per, Morrow, Monica, Orecchia, Roberto, Kent Osborne, C., Partridge, Ann H., de la Peña, Lorena, Piccart-Gebhart, Martine J., Pritchard, Kathleen I., Rutgers, Emiel J.T., Sedlmayer, Felix, Semiglazov, Vladimir, Shao, Zhi-Ming, Smith, Ian, Thürlimann, Beat, Toi, Masakazu, Tutt, Andrew, Viale, Giuseppe, von Minckwitz, Gunter, Watanabe, Toru, Whelan, Timothy, Winer, Eric P., Xu, Binghe, Coates, A. S., Winer, E. P., Goldhirsch, A., Gelber, R. D., Gnant, M., Piccart-Gebhart, M., Thürlimann, B., Senn, H.-J, André, Fabrice, Baselga, José, Bergh, Jonas, Bonnefoi, Hervé, Burstein, Harold, Cardoso, Fatima, Castiglione-Gertsch, Monica, Coates, Alan S., Colleoni, Marco, Curigliano, Giuseppe, Davidson, Nancy E., Di Leo, Angelo, Ejlertsen, Bent, Forbes, John F., Galimberti, Viviana, Gelber, Richard D., Gnant, Michael, Goldhirsch, Aron, Goodwin, Pamela, Harbeck, Nadia, Hayes, Daniel F., Huober, Jens, Hudis, Clifford A., Ingle, James N., Jassem, Jacek, Jiang, Zefei, Karlsson, Per, Morrow, Monica, Orecchia, Roberto, Kent Osborne, C., Partridge, Ann H., de la Peña, Lorena, Piccart-Gebhart, Martine J., Pritchard, Kathleen I., Rutgers, Emiel J.T., Sedlmayer, Felix, Semiglazov, Vladimir, Shao, Zhi-Ming, Smith, Ian, Thürlimann, Beat, Toi, Masakazu, Tutt, Andrew, Viale, Giuseppe, von Minckwitz, Gunter, Watanabe, Toru, Whelan, Timothy, Winer, Eric P., and Xu, Binghe

Abstract

The 14th St Gallen International Breast Cancer Conference (2015) reviewed new evidence on locoregional and systemic therapies for early breast cancer. This manuscript presents news and progress since the 2013 meeting, provides expert opinion on almost 200 questions posed to Consensus Panel members, and summarizes treatment-oriented classification of subgroups and treatment recommendations

Published
2017

9. Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

Author

Coates, A. S., Winer, E. P., Goldhirsch, A., Gelber, R. D., Gnant, M., Piccart-Gebhart, M., Thürlimann, B., Senn, H.-J, André, Fabrice, Baselga, José, Bergh, Jonas, Bonnefoi, Hervé, Burstein, Harold, Cardoso, Fatima, Castiglione-Gertsch, Monica, Coates, Alan S., Colleoni, Marco, Curigliano, Giuseppe, Davidson, Nancy E., Di Leo, Angelo, Ejlertsen, Bent, Forbes, John F., Galimberti, Viviana, Gelber, Richard D., Gnant, Michael, Goldhirsch, Aron, Goodwin, Pamela, Harbeck, Nadia, Hayes, Daniel F., Huober, Jens, Hudis, Clifford A., Ingle, James N., Jassem, Jacek, Jiang, Zefei, Karlsson, Per, Morrow, Monica, Orecchia, Roberto, Kent Osborne, C., Partridge, Ann H., de la Peña, Lorena, Piccart-Gebhart, Martine J., Pritchard, Kathleen I., Rutgers, Emiel J.T., Sedlmayer, Felix, Semiglazov, Vladimir, Shao, Zhi-Ming, Smith, Ian, Thürlimann, Beat, Toi, Masakazu, Tutt, Andrew, Viale, Giuseppe, von Minckwitz, Gunter, Watanabe, Toru, Whelan, Timothy, Winer, Eric P., Xu, Binghe, Coates, A. S., Winer, E. P., Goldhirsch, A., Gelber, R. D., Gnant, M., Piccart-Gebhart, M., Thürlimann, B., Senn, H.-J, André, Fabrice, Baselga, José, Bergh, Jonas, Bonnefoi, Hervé, Burstein, Harold, Cardoso, Fatima, Castiglione-Gertsch, Monica, Coates, Alan S., Colleoni, Marco, Curigliano, Giuseppe, Davidson, Nancy E., Di Leo, Angelo, Ejlertsen, Bent, Forbes, John F., Galimberti, Viviana, Gelber, Richard D., Gnant, Michael, Goldhirsch, Aron, Goodwin, Pamela, Harbeck, Nadia, Hayes, Daniel F., Huober, Jens, Hudis, Clifford A., Ingle, James N., Jassem, Jacek, Jiang, Zefei, Karlsson, Per, Morrow, Monica, Orecchia, Roberto, Kent Osborne, C., Partridge, Ann H., de la Peña, Lorena, Piccart-Gebhart, Martine J., Pritchard, Kathleen I., Rutgers, Emiel J.T., Sedlmayer, Felix, Semiglazov, Vladimir, Shao, Zhi-Ming, Smith, Ian, Thürlimann, Beat, Toi, Masakazu, Tutt, Andrew, Viale, Giuseppe, von Minckwitz, Gunter, Watanabe, Toru, Whelan, Timothy, Winer, Eric P., and Xu, Binghe

Abstract

The 14th St Gallen International Breast Cancer Conference (2015) reviewed new evidence on locoregional and systemic therapies for early breast cancer. This manuscript presents news and progress since the 2013 meeting, provides expert opinion on almost 200 questions posed to Consensus Panel members, and summarizes treatment-oriented classification of subgroups and treatment recommendations

Catalog

Books, media, physical & digital resources
See catalog results